Clinical Trials Logo
  1. Home
  2. Peanut Allergy
  3. NCT03352726
  4. Details
NCT03352726 Clinical Trial

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

Peanut Allergy Clinical Trial

— V712-103  

Official title:
An Open-label Phase I Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03352726
Other study ID # BIOPOT
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 24, 2017
Est. completion date June 29, 2018

Study information
Verified date July 2019
Source DBV Technologies
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

Recruitment information / eligibility
Status Completed
Enrollment 27
Est. completion date June 29, 2018
Est. primary completion date June 29, 2018
Accepts healthy volunteers No
Gender All
Age group 12 Years to 50 Years
Eligibility Main Inclusion Criteria:

- Male or female subjects aged between 12-50 years

- Physician-diagnosed peanut allergy

- Subject currently following a strict peanut-free diet

- Documented history of positive test to peanut-specific IgE (ImmunoCAP system) >0.7 kU/L

- Positive peanut SPT with a largest wheal diameter = 8 mm

Main Exclusion Criteria:

- Uncontrolled asthma

- Peanut allergen immunotherapy whatever the route, either ongoing or previously started and having lasted more than one month (>30 days)

- Topical use of steroids within the past 14 days prior to the Screening SPT

- Inability to discontinue short-acting antihistamines

- Atopic dermatitis, eczema or urticaria on the areas to be tested

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• DBV712 IHRP
DBV712 Solution for Skin Prick Test

Locations
Country Name City State
United States Children's Hospital Colorado Aurora Colorado
United States Arkansas Children's Hospital Little Rock Arkansas

Sponsors (1)
Lead Sponsor Collaborator
DBV Technologies

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU) 1 day to 2 weeks
Secondary Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) Throughout the study (1 day to 2 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05667610 - Immune-supportive Diet and Gut Permeability in Allergic Children N/A
Recruiting NCT05440643 - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Phase 1
Terminated NCT03849079 - Validation of the HYPONUT Product N/A
Completed NCT02979600 - Clinical and Biological Efficacy of Peanut Oral Immunotherapy N/A
Completed NCT01955109 - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Phase 2
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Recruiting NCT04415593 - High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety N/A
Active, not recruiting NCT04511494 - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Active, not recruiting NCT04881773 - Oral Low Doses Tolerance INduction Study for Peanuts
Completed NCT03682770 - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Phase 2
Terminated NCT03703791 - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents Phase 3
Completed NCT02916446 - Safety Study of Viaskin Peanut to Treat Peanut Allergy Phase 3
Active, not recruiting NCT02402231 - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Phase 2
Completed NCT03337542 - AR101 Real-World Open-Label Extension Study Phase 3
Recruiting NCT05476497 - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects Phase 1
Completed NCT03292484 - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Phase 3
Completed NCT03852342 - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting NCT05138757 - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Phase 1/Phase 2
Terminated NCT01897077 - The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy Phase 1/Phase 2